我們已在上線! 進一步了解
GLS

Gelesis Holdings, Inc.

已下市

GLS已於2023年4月10日下市。

 

關於: Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

員工: 93

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於GLS的最新新聞文章。

價格圖表採用Lightweight Charts™實作